[ad_1]
Washington – SANA
Scientists from the University of Texas at Austin, United States, conducted the first clinical trial of a group of drugs aimed at destroying murine phenotype cells on volunteers.
The test results were "encouraging and promising", involving 14 volunteers whose unknown cause of pulmonary fibrosis led to rapid death. Within three weeks, patients received nine doses of Dasatneb used in the treatment of leukemia and kericetin, In the components of many biological supplements also helped eliminate cells from the affected phenotype.
The patients at the end of the test were able to walk better than the previous addition to a marked improvement in their state of health because they did not suffer the side effects of the treatment used.
According to the researchers, although this test was preliminary, but examined the usefulness of the preparation in the treatment of aging diseases attributed to pulmonary disease of unknown reason.
The second test is supposed to involve 15 people with pulmonary fibrosis and 20 patients with chronic nephropathy.If the results are positive, the effectiveness of the product will be tested on a larger scale.
According to a scientific study, phenotypic cells do not die and continue to produce biochemical signals causing the aging of other cells and the body in general.
Follow the latest news via Tilgram on Smartphones via:
https://telegram.me/SyrianArabNewsAgency
Follow us through the Watts AB app:
By sending a subscription word to the number 0940777186 After storing it under Sana or (SANA).
Follow us on our website (VK) For social networks to:
http://vk.com/syrianarabnewsagency
Source link
